First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies
Steven T. Bird(Brigham and Women's Hospital), Ira Krefting(Center for Drug Evaluation and Research), Erica Radden(Center for Drug Evaluation and Research), Elnara Fazio‐Eynullayeva(Center for Drug Evaluation and Research), Leyla Şahin, Patty Greene(United States Food and Drug Administration), Karen B. Bleich(Center for Drug Evaluation and Research), Carolyn McCloskey(Center for Drug Evaluation and Research), Mayura Shinde(Center for Drug Evaluation and Research), Corinne Woods(United States Food and Drug Administration), Tamara Johnson(Center for Drug Evaluation and Research), Kate Gelperin(United States Food and Drug Administration)
Cited by 56
Related Papers
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
|Canadian Medical Association Journal|2012|120
Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers
|American Journal of Obstetrics and Gynecology|2013|118
Isotretinoin and Risk for Inflammatory Bowel Disease
|JAMA Dermatology|2013|93
Risk of acute kidney injury associated with the use of fluoroquinolones
|Canadian Medical Association Journal|2013|89